| Name | RAGE antagonist peptide acetate |
| Description | RAGE antagonist peptide acetate is an advanced antagonist of glycation end products (RAGE). RAGE antagonist peptide acetate possesses anti-tumor and anti-inflammatory activities. RAGE antagonist peptide acetate prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. |
| In vitro | In cancer cells, RAGE antagonist peptide acetate reduces the ability of the ligands to stimulate RAGE activation of NFκB[2]. |
| In vivo | In mice bearing asthma, RAGE antagonist peptide acetate (RAP; 4 mg/kg; i.p.) blunts airway reactivity, airway inflammation and goblet cell metaplasia, and decreases release of Th2 cytokines. RAGE antagonist peptide acetate also reduces total, cytoplasmic and nuclear levels of β-catenin, enhanced β-catenin phosphorylation at Ser33/37/Thr41, which triggers ubiquitination, down-regulated expression of β-catenin targeted genes, and tends to keep β-catenin at the cytomembrane, shifting β-catenin from a signalling active pattern to an adhesive function[1]. RAGE antagonist peptide acetate reduces the growth and metastasis of pancreatic tumors and also inhibited glioma tumor growth. RAGE antagonist peptide acetate (100 μg) inhibits RAGE-mediated Basal NFκB Activity in PDAC cells in vivo[2]. |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Keywords | RAGE antagonist peptide acetate | RAGE antagonist peptide Acetate |
| Inhibitors Related | Anle138b | BSBM7 | Notoginsenoside R1 | Geniposide | Deferoxamine Mesylate | Tramiprosate | Dihydroergocristine mesylate | Rutin | Methyl tridecanoate | DAPT |
| Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Peptide Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
United States
